Stacy Cline Amin recently spoke to Law360 about the potential consequences of the U.S. Supreme Court’s overturning of the Chevron doctrine and weakening the authority of federal agencies, likely making the drug regulatory landscape more volatile.
Stacy said the trend of plaintiffs choosing to file in a friendly forum makes it more likely courts will issue conflicting opinions on agency power: “One of the biggest potential fallouts of this decision is the possibility for these split decisions in different circuits — when the same issue, maybe not by the same parties, but the same issue, could get litigated in multiple places.”
Read the full article.